Breast Disease

Treatment

Five-Year Overall Survival of Female Patients With Breast Cancer by Raceᵃ (N= 9550)

2008-2017

Number at Risk Year 1 Year 2 Year 3 Year 4 Year 5
Caucasian (N= 8207) 7923 6938 5952 4458 3135
African-American (N= 1343) 1263 1105 889 694 495

ᵃSelf-Reported

Five-Year Overall Survival of Female Patients With Breast Cancer by Hormone Receptor Status (N= 7888)

2008-2017

Number at Risk Year 1 Year 2 Year 3 Year 4 Year 5
ER/PR Negative (N = 1635) 1535 1281 1039 799 566
ER/PR Positive (N = 6253) 6030 5366 4419 3580 2561

ER= estrogen receptor, PR= progesterone receptor

Five-Year Overall Survival of Female Patients With Breast Cancer by HER2 Status (N= 6226)

2008-2017

Number at Risk Year 1 Year 2 Year 3 Year 4 Year 5
HER2 Negative (N = 5154) 4912 4153 3180 2341 1475
HER2 Positive (N = 1072) 1031 889 698 507 324

HER2= human epidermal growth factor receptor 2

Five-Year Overall Survival of Female Patients With Stages I-III Breast Cancer by Estrogen Receptor, Progesterone Receptor, and HER2 Status (N= 6348)

2008-2017

Number at Risk Year 1 Year 2 Year 3 Year 4 Year 5
ER/PR Positive (N = 4835) 4710 4169 3412 2742 1942
HER2 Positive (N = 866) 850 740 595 438 288
Triple-Negative (N = 647) 717 574 432 296 182

ER= estrogen receptor, HER2= human epidermal growth factor receptor 2, PR= progesterone receptor

Five-Year Overall Survival of Female Patients With Stageᵃ 0 and I Breast Cancer (N= 5672)

2008-2017

Number at Risk Year 1 Year 2 Year 3 Year 4 Year 5
Stage 0 CC (N = 1670) 1627 1460 1233 973 714
Stage I CC (N = 4002) 3890 3445 2821 2238 1578

CC= Cleveland Clinic, NCDB= National Cancer Database

ᵃAJCC stage I-IV breast cancer

ᵇReference group data from the National Cancer Database (Commission on Cancer of the American College of Surgeons and the American Cancer Society) 2000-2002, as reported in: Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer Science & Business Media; 2010.

Five-Year Overall Survival of Female Patients With Stageᵃ IIA and IIB Breast Cancer (N= 2606)

2008-2017

Number at Risk Year 1 Year 2 Year 3 Year 4 Year 5
Stage IIA (N = 1788) 1717 1505 1228 981 703
Stage IIB (N = 818) 791 677 551 436 290

CC= Cleveland Clinic, NCDB= National Cancer Database

ᵃAJCC stage I-IV breast cancer

ᵇReference group data from the National Cancer Database (Commission on Cancer of the American College of Surgeons and the American Cancer Society) 2000-2002, as reported in: Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer Science & Business Media; 2010.

Five-Year Overall Survival of Female Patients With Stageᵃ IIIA and IIIB Breast Cancer (N= 703)

2008-2017

Number at Risk Year 1 Year 2 Year 3 Year 4 Year 5
Stage IIIA (N = 539) 522 438 346 266 184
Stage IIIB (N = 164) 147 122 84 57 40

CC= Cleveland Clinic, NCDB= National Cancer Database

ᵃAJCC stage I-IV breast cancer

ᵇReference group data from the National Cancer Database (Commission on Cancer of the American College of Surgeons and the American Cancer Society) 2000-2002, as reported in: Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer Science & Business Media; 2010.

Five-Year Overall Survival of Female Patients With Late-Stage Breast Cancer (N= 595)

2008-2017

Number at Risk Year 1 Year 2 Year 3 Year 4 Year 5
Stage IIIC (N = 178) 166 132 99 72 55
Stage IV (N = 417) 319 243 156 101 68

CC = Cleveland Clinic, NCDB = National Cancer Database

ᵃAJCC stage I-IV breast cancer

ᵇReferance group data from the National Cancer Database (Commission on Cancer of the American College of Surgeon and the American Cancer Society) 2000-2002, as reported in: Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer Science & Business Media; 2010